All In Biotech

Drug Trial Radar · NCT06602739

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

A Randomized, Double-Masked, Placebo-Controlled Study to Assess the Efficacy and Safety of REGN5713-5715 to Reduce Signs and Symptoms of Allergic Conjunctivitis in Participants With Birch Pollen Allergy

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

54

Actual

Start

Nov 19, 2024

Primary completion

Apr 23, 2025

Study completion Aug 2, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).

Conditions

  • Allergic Conjunctivitis

Interventions

  • REGN5713Drug

    Administered per protocol

  • REGN5715Drug

    Administered per protocol

  • PlaceboDrug

    Administered per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular itch score in response to birch allergen challengeTime frame: At Day 8 post-Conjunctival Allergen Challenge (CAC)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Andover Eye Associates

    Andover, Massachusetts

  • Clinique de Specialisee en Allergie de la Capitale

    Québec, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.